Author: 16by9

Physiomics plc is pleased to announce that it has signed its first contract for developing Virtual Tumour Clinical with a global pharmaceutical company. The client is Merck Serono, the biopharmaceutical division of Merck, Germany. Revenue from the contract will fall in the 2014/2015 and 2015/2016 financial years and is in the region of the total value of all of Physiomics 2013/2014 sales. As such it...

Chairman’s Statement   Summary of Results in the year ended 30 June 2014   The turnover of the Company increased by 12% to £267,903 (2013: £240,000). The operating loss reduced by 15% to £465,265 (2013: £548,342). On 30 June 2014 the surplus of shareholders’ funds was £136,487 (2013: £255,821). This year, Physiomics has made good progress advancing Virtual Tumour Clinical and has broadened its offering into the personalised medicine...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is delighted to announce that Merck & Co., a top 5 pharmaceutical company, has disclosed that it is a customer of Physiomics.   Merck & Co. published a paper in CPT: Pharmacometrics and Systems Biology (part of Nature Group) in which Virtual Tumour was specified as a technology which had helped their decision-making process...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a further extension to a Virtual Tumour project with a major global pharmaceutical company, first announced on 1st March 2012.  The extension will cover predicting optimal regimens for a further candidate compound and should be completed by the end of 2014...

Dr Eric Fernandez will present EasyAP at the Safety Pharmacology Society Meeting in Washington, DC, from the 19th to 22nd of October....

Physiomics is pleased to announce that it has now launched its predictive web-based platform for cardiac toxicity. EasyAP™ provides cardiac action potential time course simulations to facilitate the prediction of cardiac toxicity and compound selection. Read more....